Histiocitosis de células de Langerhans con implicación oral: a propósito de un caso

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

La proliferación desordenada de histiocitos muy similares a células de Langerhans da lugar a un tipo de patología que se conoce como histiocitosis de células de Langerhans. La histiocitosis de células de Langerhans es una enfermedad rara, poco frecuente, de etiología no muy clara y que se caracteriza por manifestaciones de variable presentación: desde una afectación de varios órganos o sistemas y con una mortalidad muy elevada, hasta una lesión única, bien sea con compromiso óseo o con patología pulmonar, de favorable evolución, incluso hasta la regresión espontánea. Es frecuente que exista sólo patología oral o que ésta acompañe al resto de la sintomatología general. A nivel bucal, puede presentar lesiones óseas líticas en un único o en varios puntos; se pueden ver, así mismo, fracturas patológicas de la mandíbula, dolor, úlceras bucales, compromiso periodontal con bolsas periodontales marcadas, acusada movilidad de piezas dentales con pérdida prematura de dientes, erupción precoz de dientes, etc.

Translated abstract

Langerhans cell histiocytosis (LCH) is a rare disorder of unknown etiology, characterized by disorganized proliferation of histiocytes similar to Langerhans cells. Variable clinical manifestations are observed in this entity: from acute multisistemic disease, associated with high mortality, to bone or lung lesions of favorable prognosis. Oral involvement may be present with or without other clinical signs. Osteolytic bone lesions, isolated or multiple areas of the maxilla, pathological mandibular fractures, pain, eritematous ulcerations, periodontal disease that may lead to periodontal deep pockets and alveolar bone loss, dental mobility, premature tooth eruption and premature dental loss may exist as oral manifestations of the disease.

Related collections

Most cited references 50

Record: found
Abstract: found
Article: not found

Risk factors for diabetes insipidus in langerhans cell histiocytosis.

N Grois, U Pötschger, H Prosch … (2006)

Diabetes insipidus (DI) is the most frequent central nervous system (CNS)-related permanent consequence in Langerhans cell histiocytosis (LCH), which mostly requires life-long hormone replacement therapy. In an attempt to define the population at risk for DI, 1,741 patients with LCH registered on the trials DALHX 83 and DALHX 90, LCH I and LCH II were studied. Overall 212 of 1,741 patients (12%) was reported to have DI. In 102 of 1,741 patients (6%) DI was present at diagnosis of LCH. One thousand one hundred eighty three of 1,539 patients without DI at diagnosis had follow up information. One hundred ten of these (9%) later developed DI. The risk of developing DI was 20% at 15 years after diagnosis. Multisystem disease patients at diagnosis carried a 4.6-fold risk for DI compared to single system patients. Craniofacial lesions, in particular in the "ear," "eye," and oral region were associated with a significantly increased risk for DI (relative hazard rate, RHR 1.7), independent of the extent of disease. No influence of the duration of therapy could be determined, but the duration of initial disease activity (RHR 1.5) and the occurrence of reactivations (RHR 3.5) significantly increased the risk for DI. Patients with multisystem disease and craniofacial involvement at diagnosis, in particular of the "ear," "eye," and the oral region carry a significantly increased risk to develop DI during their course. This risk is augmented when the disease remains active for a longer period or reactivates.

0 comments Cited 61 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.

H Gadner, N Grois, M Aricò … (2001)

To compare 2 active agents, vinblastine and etoposide, in the treatment of multisystem Langerhans' cell histiocytosis (LCH) in an international randomized study. One hundred forty-three untreated patients were randomly assigned to receive 24 weeks of vinblastine (6 mg/m(2), given intravenously every week) or etoposide (150 mg/m(2)/d, given intravenously for 3 days every 3 weeks), and a single initial dose of corticosteroids. Vinblastine and etoposide were equivalent (P > or = .2) in all respects: response at week 6 (57% and 49%); response at the last evaluation (58% and 69%); toxicity (47% and 58%); and probability of survival (76% and 83%) [corrected], of disease reactivation (61% and 55%), and of developing permanent consequences (39% and 51%) including diabetes insipidus (22% and 23%). LCH reactivations were usually mild, as was toxicity. All children > or = 2 years old without risk organ involvement (liver, lungs, hematopoietic system, or spleen) survived. With such involvement, lack of rapid (within 6 weeks) response was identified as a new prognostic indicator, predicting a high (66%) mortality rate. Vinblastine and etoposide, with one dose of corticosteroids, are equally effective treatments for multisystem LCH, but patients who do not respond within 6 weeks are at increased risk for treatment failure and may require different therapy.

0 comments Cited 59 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Incidence of Langerhans cell histiocytosis in children: a population-based study.

Jan-Inge Henter, Anthony J. Karis, Désirée Gavhed … (2008)

Langerhans cell histiocytosis is a rare disease of unknown etiology. We wanted to assess the population-based incidence of LCH in a well-defined cohort of children. We identified all children <15-years old treated with LCH during the 10 years period 1992-2001 at the Department of Pediatrics, Karolinska University Hospital in Stockholm, the referral center for children with LCH in Stockholm County. We also contacted the Departments of Dermatology, Orthopedics, and Neurosurgery for possible additional patients. Twenty-nine children (16 males) with LCH were identified, with a median age at diagnosis of 3.8 years (2 months-13.7 years). All children but one had a definitive diagnosis of LCH. The minimum incidence of LCH is estimated to 8.9/10(6) children per year. At diagnosis, 20 children (69%) had single system (SS) and 9 (31%) multisystem (MS) manifestations. Five of the 20 children with SS eventually developed MS disease, thus 14 (48%) had MS involvement at the maximal extent of disease (4.3/10(6) children per year). Interestingly, 22 children (76%) were diagnosed during the fall (September-November, n = 12) and winter (December-February, n = 10) seasons, as compared to seven children during the spring (March-May = 1) and summer (June-August = 6) seasons (P = 0.005, Chi-square). The incidence of childhood LCH in our study is higher than previously reported. In our patient cohort, LCH was more commonly diagnosed during the fall and winter season as compared to the spring and summer season. Whether this seasonal variation can be confirmed in larger studies and whether it has relevance for LCH pathophysiology remains to be elucidated. (c) 2008 Wiley-Liss, Inc.